#Netherlands #Xeltis #aXess #Eindhoven #Nephrology

Xeltis Expands Medical Advisory Board with Leading Nephrology Experts

On March 11, 2025, Xeltis, an innovative leader in medical implant technology, disclosed the appointment of two prominent experts in clinical nephrology to its Medical Advisory Board (MAB). This strategic move highlights the company’s commitment to advancing its flagship product, aXess, which aims to revolutionize hemodialysis vascular access solutions.

New Leadership in Nephrology

The newly appointed members are Dr. An De Vriese and Dr. Haimanot (Monnie) Wasse, both of whom bring substantial expertise in nephrology and patient care. Dr. De Vriese currently heads the Division of Nephrology and Infectious Disease at AZ Sint-Jan Brugge, in addition to serving as a Guest Professor at Ghent University. On the other hand, Dr. Wasse holds the position of Interim Chair of the Department of Internal Medicine, and Chief of Nephrology at Rush University Medical Center.

These esteemed professionals will collaborate with the existing board members to provide invaluable clinical insights and strategic direction as Xeltis prepares for the commercialization of aXess. Eliane Schutte, CEO of Xeltis, expressed her enthusiasm, stating, "The appointments reflect significant validation of our technology from leaders in the nephrology field, and their combined expertise will be critical as we move aXess through its pivotal trials in the EU and US."

The Promise of aXess

aXess represents an innovative approach to vascular access for dialysis patients. It aims to address key challenges related to current treatment options, including the frequent need for reinterventions and associated risks such as infections. This product merges the benefits of a fistula with the expedited access provided by an arteriovenous (AV) graft, without the complications that often accompany traditional methods.

With pivotal trials already progressing in both the European Union and the United States, recent milestones indicate that enrolment has been completed in the EU, while several patients have begun to receive implants in the US. The anticipated primary readouts from the EU pivotal trial are scheduled for mid-2025.

Expert Perspectives

Dr. An De Vriese expressed her excitement about joining the Xeltis MAB, noting, "It is an honor to contribute to this pivotal moment in the Company’s journey. I am truly inspired by Xeltis' innovative technology, which has the potential to significantly enhance patient outcomes by eliminating the frequent interventions and complications faced by patients with end-stage renal disease."

Similarly, Dr. Monnie Wasse remarked, "Having monitored Xeltis' clinical advancement closely, I recognize the enormous potential of aXess. I look forward to utilizing my expertise in interventional nephrology to advance this groundbreaking medical technology further."

About Xeltis

Founded with the goal of transforming medical treatments, Xeltis is dedicated to developing revolutionary implants that facilitate the natural formation of living, durable blood vessels. Their proprietary Endogenous Tissue Restoration (ETR) platform underpins their innovative approach, which regenerates a patient’s own tissue, culminating in sustainable and functional vessels that enhance the quality of life for countless individuals requiring hemodialysis or cardiovascular solutions.

The Xeltis team, headquartered in the Netherlands and the USA, is continuously focusing on advancing technologies with wide-reaching applications that promise to address significant vascular and cardiovascular diseases. Their lineup of stakeholders includes prominent investors such as DaVita Venture Group and the European Innovation Council.

For more information about Xeltis and its pioneering work in the field of medical technology, visit their official website at Xeltis.com.